Authors: Peterson DJ. PMID: Abstract Keywords: Source: https://ago.nebraska.gov/sites/ago.nebraska.gov/files/docs/opinions/21-017_0.pdf Archive: https://archive.is/EoVhB

This study aimed to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).

Authors: Nogues X, Overjero D, Pineda-Moncus M, Bouillon R PMID: 34097036 PMCID: PMC8344647 DOI: 10.1210/clinem/dgab405 Abstract Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective: This work aims to elucidate the effect [...]

Authors: Malone B, Campbell EA PMID: 34518697 DOI: 10.1038/s41594-021-00657-8 Abstract Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the [...]

Authors: Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu R, Fadel R et al. PMID: 33693506 PMCID: PMC7989618 DOI: 10.1093/bioinformatics/btab163 Abstract Motivation: COVID-19 has several distinct clinical phases: a viral replication phase, an inflammatory phase and in some patients, a hyper-inflammatory phase. High mortality is associated with patients developing cytokine storm syndrome. Treatment of [...]

Authors: Elamir YM, Amir H, Lim S, Rana Y, Lopez CG, Omar A PMID: 34508882 PMCID: PMC8425676 DOI: 10.1016/j.bone.2021.116175 Abstract The systemic illness associated with SARS-CoV-2 infection results in hospitalization rate of 380.3 hospitalizations per 100,000 population, overwhelming health care systems. Vitamin D regulates expression of approximately 11,000 genes spanning many physiologic functions that include [...]

Authors: Kabinger F, Stiller C, Schmitzova J, Kokic G PMID: 34381216 PMCID: PMC8437801 DOI: 10.1038/s41594-021-00651-0 Abstract Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, [...]

Treatment for coronavirus disease 2019 (COVID19) pneumonia remains empirical and the search for therapies that can improve outcomes continues. Melatonin has been shown to have anti-inflammatory, antioxidant, and immune-modulating effects that may address key pathophysiologic mechanisms in the development and progression of acute respiratory distress syndrome (ARDS), which has been implicated as the likely cause of death in COVID19. We aimed to describe the observable clinical outcomes and tolerability of high-dose melatonin (hdM) given as adjuvant therapy in patients admitted with COVID19 pneumonia.

Authors: Yu LM, Bafadhel M, Doeward J, Hayward G PMID: 34388395 PMCID: PMC8354567 DOI: 10.1016/S0140-6736(21)01744-X Abstract Background: A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital [...]

Authors: Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BM PMID: 33961695 PMCID: PMC8136050 DOI: 10.1093/infdis/jiab247 Abstract Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concentrate in genomes of RNA viruses during viral replication. β-d-N4-hydroxycytidine (NHC, initial metabolite of molnupiravir) is >100-fold more active [...]